Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Buy
55
LCTX Quote, Financials, Valuation and Earnings
Last price:
$0.85
Seasonality move
:
-0.75%
Day range:
$0.80 - $0.86
52-week range:
$0.37 - $1.15
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.09x
P/B ratio:
2.50x
Volume:
4.5M
Avg. volume:
1.4M
1-year change:
-5.94%
Market cap:
$197.5M
Revenue:
$9.5M
EPS (TTM):
-$0.08
Analysts' Opinion
-
Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.92, Lineage Cell Therapeutics has an estimated upside of 352.9% from its current price of $0.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.86.
Fair Value
-
According to the consensus of 5 analysts, Lineage Cell Therapeutics has 352.9% upside to fair value with a price target of $3.92 per share.
LCTX vs. S&P 500
-
Over the past 5 trading days, Lineage Cell Therapeutics has overperformed the S&P 500 by 20.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Lineage Cell Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lineage Cell Therapeutics has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Lineage Cell Therapeutics reported revenues of $1.5M.
Earnings Growth
-
Lineage Cell Therapeutics has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Lineage Cell Therapeutics reported earnings per share of -$0.02.
Enterprise value:
148.2M
EV / Invested capital:
1.91x
Price / LTM sales:
19.09x
EV / EBIT:
--
EV / Revenue:
15.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.3M
Return On Assets:
-15.21%
Net Income Margin (TTM):
-169.57%
Return On Equity:
-22.68%
Return On Invested Capital:
-22.68%
Operating Margin:
-433.09%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $11.9M | $8M | $9.6M | $1.4M | $1.5M | |
| Gross Profit | $11.2M | $7.4M | $9.3M | $1.3M | $1.5M | |
| Operating Income | -$22.8M | -$24.8M | -$21.3M | -$6.7M | -$6.5M | |
| EBITDA | -$22M | -$24.1M | -$20.7M | -$6.5M | -$6.3M | |
| Diluted EPS | -$0.14 | -$0.13 | -$0.08 | -$0.04 | -$0.02 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $64.6M | $81.9M | $49.7M | $45.7M | $50M | |
| Total Assets | $127.9M | $144.5M | $113.2M | $108.5M | $111.8M | |
| Current Liabilities | $6.6M | $24.6M | $17.2M | $16.9M | $13.1M | |
| Total Liabilities | $11.4M | $59.3M | $44.2M | $37.5M | $34.1M | |
| Total Equity | $116.6M | $85.2M | $69M | $71M | $77.7M | |
| Total Debt | $523K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.1M | -$23.1M | -$22.2M | -$5.8M | -$4.9M | |
| Cash From Investing | -$30.7M | $31M | -$367K | -$38K | $1.9M | |
| Cash From Financing | $1.1M | $20.4M | $26.9M | $14M | $5M | |
| Free Cash Flow | -$32.6M | -$23.6M | -$22.8M | -$5.8M | -$5M | |
LCTX
Sector
Market Cap
$197.5M
$32.6M
Price % of 52-Week High
75.2%
47.07%
Dividend Yield
0%
0%
Shareholder Yield
-26.41%
-0.74%
1-Year Price Total Return
-5.94%
-37.62%
Beta (5-Year)
1.517
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.73
200-day SMA
Buy
Level
$0.66
Bollinger Bands (100)
Buy
Level
0.45 - 0.67
Chaikin Money Flow
Sell
Level
-73.2M
20-day SMA
Buy
Level
$0.65
Relative Strength Index (RSI14)
Buy
Level
78.36
ADX Line
Buy
Level
52.97
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$0.53
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
39.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3033)
Sell
CA Score
(Annual)
Level (-0.5917)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.4171)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Stock Forecast FAQ
In the current month, LCTX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LCTX average analyst price target in the past 3 months is $3.92.
-
Where Will Lineage Cell Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lineage Cell Therapeutics share price will rise to $3.92 per share over the next 12 months.
-
What Do Analysts Say About Lineage Cell Therapeutics?
Analysts are divided on their view about Lineage Cell Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lineage Cell Therapeutics is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Lineage Cell Therapeutics's Price Target?
The price target for Lineage Cell Therapeutics over the next 1-year time period is forecast to be $3.92 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LCTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lineage Cell Therapeutics is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LCTX?
You can purchase shares of Lineage Cell Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lineage Cell Therapeutics shares.
-
What Is The Lineage Cell Therapeutics Share Price Today?
Lineage Cell Therapeutics was last trading at $0.85 per share. This represents the most recent stock quote for Lineage Cell Therapeutics. Yesterday, Lineage Cell Therapeutics closed at $0.86 per share.
-
How To Buy Lineage Cell Therapeutics Stock Online?
In order to purchase Lineage Cell Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.
Buy
59
SYM alert for Jun 17
Symbotic [SYM] is down 3.91% over the past day.
Sell
43
TNXP alert for Jun 17
Tonix Pharmaceuticals Holding [TNXP] is down 5.6% over the past day.
